IP Library Granted Patent US 9,902,756
Granted Patent B2
US 9,902,756 · App. 14/442,832 · Granted Feb 27, 2018

Gonorrheal MtrE peptides and vaccines

Inventors: Ann Jerse (Rockville, MD); Amanda Derocco (Garrett Park, MD)
Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
C07K14/22A61K39/095C07K16/1214C07K16/1217A61K38/00A61K2039/543A61K2039/55505C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,756
App. No.
14/442,832
Granted
Feb 27, 2018
Kind
B2
Abstract

The invention is directed to MtrE peptides and their use in gonorrhea vaccines.

Claims (11)

1. A method of immunizing a subject against Neisseria gonorrhoeae ( N. gonorrhoeae ) comprising administering a pharmaceutical composition to the subject in an immunogenically effective amount, wherein the composition comprises a pharmaceutically acceptable carrier and an immunogenic peptide comprising an amino acid sequence that is at least 95% identical to residues 23-467 of SEQ ID NO:1.

2. The method of claim 1 , wherein the immunogenic peptide comprises an amino acid sequence that is at least 99% identical to residues 23-467 of SEQ ID NO:1.

3. The method of claim 2 , wherein the immunogenic peptide comprises the amino acid sequence of residues 23-467 of SEQ ID NO:1.

4. The method of claim 1 , wherein the pharmaceutical composition further comprises at least one adjuvant.

5. The method of claim 4 , wherein the at least one adjuvant is selected from the group consisting of cholera toxin (CT), CpG DNA (CpG), resquimod (R 848), Pam3CSK4, interleukin 12 (IL-12) and monophosphoryl A (MPLA).

6. The method of claim 5 , wherein the pharmaceutical composition comprises at least two adjuvants selected from the group consisting of CT, CpG, R 848, Pam3CSK4, IL-12 and MPLA.

7. The method of claim 6 , wherein the at least two adjuvants are (a) CpG and R 848, (b) CpG and Pam3CSK4 or (c) CpG and MPLA.

8. The method of claim 1 , wherein the immunogenic peptide further comprises a histidine tag (his tag) or a lysine tag (lys tag).

9. The method of claim 1 , wherein the pharmaceutical composition is administered subcutaneously or intranasally.

10. The method of claim 1 , wherein the pharmaceutical composition comprises at least one additional immunogen in addition to the immunogenic peptide.

11. The method of claim 10 , wherein the at least one additional immunogen is a peptide fragment of a MtrE subunit of the gonococcal MtrC-MtrD-MtrE (MtrCDE) active efflux pump from N. gonorrhoeae.

Assignments (1)
CONFIRMATORY LICENSE Recorded Oct 3, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039921/0462 →
Continuity (2)
Provisional Application 61727451 · Nov 16, 2012
Related Publication 20150291666A1 · Oct 15, 2015